Diagnostics as a Service for weight loss programmes: which blood tests the medicines and the German guideline call for
Weight loss medicines do not require blood monitoring, and neither European label sets a panel, a recheck or a stopping rule. The German obesity guideline does recommend a work-up, it belongs to the assessment rather than the medicine, and one society that signed it objects to part of it.
Written by
Robert Jakobson
Published on
September 29, 2026
A Diagnostics as a Service weight loss programme is often built on the belief that the medicines themselves require blood monitoring. That belief is not what the European product information says. The product information for semaglutide sold as Wegovy and for tirzepatide sold as Mounjaro asks for no panel before the first dose and no test at a fixed interval after it.12
There is still a case for blood testing in a weight loss programme, but it rests on different grounds. It comes from the German treatment guideline for obesity, where the blood work belongs to the assessment of the condition rather than to the prescription. One of the societies that signed that guideline objects to part of it. This article sets out what the medicines ask for, what the guideline asks for, where the objection lies, and who pays.
Do the weight loss medicines require blood tests?
The two documents ask for none, with one narrow exception set out at the end of this section. Neither the European product information for semaglutide sold as Wegovy nor the one for tirzepatide sold as Mounjaro sets a baseline panel, a scheduled recheck, or any stopping rule based on a laboratory value.12
Neither the Wegovy nor the Mounjaro product information asks for a blood panel before starting, a scheduled recheck, or a stopping rule based on a laboratory value. Source: the European Medicines Agency product information for both medicines, sections 4.2 and 4.4, read 21 September 2026.
Both documents do mention a laboratory value, but as a warning rather than as an instruction to test. Each states that a raised pancreatic enzyme on its own, without other signs, does not predict inflammation of the pancreas.12 As we read it, that warning argues against reading a single value in isolation. It does not argue for a routine panel.
The monitoring the two documents do name happens in the clinic or at home rather than in a laboratory. Both ask that people with diabetic eye disease be watched closely and treated to clinical guidelines.12
Where one of these medicines is added to a sulphonylurea or to insulin, the monitoring named is blood glucose, measured by the person themselves so that the other medicine can be adjusted.2
The one laboratory instruction is in the Wegovy document alone. It concerns an interaction with another medicine rather than the weight loss treatment on its own, so it applies only where that other medicine is already in use. Where semaglutide is started in somebody already taking warfarin or another coumarin derivative, the document recommends frequent monitoring of INR.1
What does the German obesity guideline recommend?
A work-up, and the work-up belongs to the condition rather than to the prescription. The current version of the guideline is 5.0 of October 2024, and it names its markers in three separate recommendations.3
The German obesity guideline recommends thyroid stimulating hormone, then cholesterol with fasting glucose, then triglycerides, uric acid, creatinine and albumin in urine. The family doctors' society objects to the third group being routine. Source: S3-Leitlinie Adipositas, AWMF 050/001, version 5.0 of October 2024.
Thyroid stimulating hormone, to look for an underactive thyroid as a cause, which the guideline gives as an expert consensus recommendation.3
Total cholesterol with LDL and HDL cholesterol and fasting glucose, which together judge heart and metabolic risk.3
Triglycerides and uric acid, then creatinine with the estimated filtration rate and albumin measured in the urine, which is the group one of the signing societies objects to as a routine.3
The purpose behind that list matters more than the list itself, because none of it is monitoring a medicine. All of it is working out what is going on with somebody before deciding what to do. That is the step a remote weight loss service can most easily leave out.
Where the blood step belongs in a Diagnostics as a Service weight loss programme
Before the prescribing decision rather than after it, if you follow the guideline's own purpose for these markers. The markers answer questions that change what you do next. They show whether an underactive thyroid is part of the cause, what the heart and metabolic risk looks like, and how the kidneys are working. Which of them a given person needs is a decision for the clinician in front of them.
A second draw later has a different purpose, which is to show the person what has changed. None of the three recommendations sets an interval for one, so a second draw is a product decision rather than a clinical requirement. Be clear with yourself about which of the two you are selling.
Who disagrees with the German obesity guideline?
The general practitioners' society does, even though it took part in writing the guideline. It states in the same document that the third group of markers, meaning the triglycerides, the uric acid, the creatinine and the urine albumin, should not be collected routinely at the primary care level.3
That objection belongs in your own copy. A programme that quotes the guideline and leaves the objection out is selling a certainty the guideline itself does not have.
Who pays for a weight loss blood panel in Germany?
The person does, at least for the medicine. German statutory insurance excludes medicines whose use is mainly about raising quality of life, and the law names weight reduction, appetite suppression and body weight regulation among them.4
That exclusion is written about the medicine rather than about a blood panel. Read together with the guideline, it suggests that a work-up sold as part of a privately paid weight loss programme is bought privately as well. The law does not say that in so many words. A practice's own regional association settles what may be billed to statutory cover.
What the exclusion does settle is the setting. Somebody buying one of these medicines in Germany is already paying for it themselves. A blood work-up is therefore another line on a bill they expect, rather than the first line on a bill they do not.
What should a weight loss programme ask a supplier?
Ask the questions a clinician would ask rather than the ones that compare most easily. What a panel costs and how quickly a result comes back are easy to get and easy to line up side by side. The harder questions are which markers are on the panel, whether a result a year later can be compared with this one, and who speaks to somebody whose result is abnormal.
What a Diagnostics as a Service supplier has to answer for a clinician
Those harder questions come to four, three clinical and one about where a draw actually happens.
Can you run the guideline's markers as one panel, and what exactly is on it?
Where would somebody on our programme actually go to give a sample?
If a marker is measured again a year later, what keeps the two results on the same footing?
What happens when a result is abnormal, and whose job is that conversation?
Settle the last of those first. A remote programme may be the only clinical contact somebody has had in a long time.
Where Aniva is on this
One company runs the ordering, the kits, the collection and the accredited laboratory work behind those markers. Because it is one company, a first measurement and a later one come from the same service rather than from two. The collection network is Aniva's own rather than a subcontracted one. The whole arrangement is a single contract under your own brand name.
What stays with you is the clinical judgement. Which markers a given person needs, and what a result means for that person, is decided by your clinicians. Whether the general practitioners' objection should change your panel is a disagreement between medical societies rather than a question a supplier settles.
Seeing the panel and the collection network beside your own programme is quicker than reading about either. You can do that when you book a demo.
Notes and sources
European Medicines Agency, Wegovy product information, sections 4.4 and 4.5. Section 4.4 sets no routine laboratory monitoring, states that raised pancreatic enzymes alone do not predict acute pancreatitis without other signs, and asks that people with diabetic retinopathy be monitored closely. Section 4.5 recommends frequent monitoring of INR where semaglutide is started in somebody already taking warfarin or another coumarin derivative. Read 21 September 2026. www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf
S3-Leitlinie Prävention und Therapie der Adipositas, AWMF register 050/001, version 5.0 of October 2024, recommendations 3.14, 3.16 and 3.17, and the DEGAM statement in the same document that the markers in 3.17 should not be collected routinely at the primary care level. register.awmf.org/assets/guidelines/050-001l_S3_Praevention-Therapie-Adipositas_2024-10.pdf
Paragraph 34 of the German social code, book five, which excludes from statutory cover medicines used mainly to raise quality of life, naming weight reduction, appetite suppression and body weight regulation. www.gesetze-im-internet.de/sgb_5/__34.html
This article describes what medicine labels and a German treatment guideline say about blood testing around weight loss care. It is general information and not medical advice, and clinical decisions belong to a clinician.
Add blood testing to your business
Aniva provides the labs, the test kits, the shipping, the software and the data protection paperwork. You offer blood tests under your own brand. Tell us which tests you need and we will show you how it works.
